PURPOSE: Adenocarcinomas of the ampulla of Vater demonstrate a characteristic histology but vary significantly in outcome. As a consequence, prognostic factors for these cancers are poorly defined. The caudal-type homeodomain transcription factors 1 (CDX1) and 2 (CDX2) regulate axial development and intestinal differentiation. We assessed the expression of these putative intestinal epithelial-specific transcription factors and their influence on patient outcome. PATIENTS AND METHODS: Fifty-three resected carcinomas of the ampulla of Vater, 31 pancreatic ductal adenocarcinomas, and 15 extrahepatic biliary carcinomas were analyzed for CDX1 and CDX2 expression using immunohistochemistry. RESULTS: Forty percent of carcinomas of the ampulla of Vater but less than 5% of pancreatic and biliary adenocarcinomas expressed CDX. Expression of CDX was associated with a better prognosis (P = .0009). Individually, both CDX1 (P = .02) and CDX2 (P = .02) expression were associated with a survival advantage on univariate analysis. Advanced T stage (P = .02), lymph node metastases (P = .004), and vascular space invasion (P = .0009) were associated with a poor prognosis. Multivariate analysis revealed vascular space invasion (P = .01) and CDX expression (P = .01) to be independent prognostic factors. CONCLUSION: Expression of CDX was an independent marker of outcome in patients with resected adenocarcinoma of the ampulla of Vater. Expression of CDX may distinguish good prognosis intestinal-like tumors, which potentially arise within intestinal epithelium, from poorer prognosis pancreatobiliary tumors, which arise in adjacent pancreatic and/or biliary ductal epithelium.
PURPOSE:Adenocarcinomas of the ampulla of Vater demonstrate a characteristic histology but vary significantly in outcome. As a consequence, prognostic factors for these cancers are poorly defined. The caudal-type homeodomain transcription factors 1 (CDX1) and 2 (CDX2) regulate axial development and intestinal differentiation. We assessed the expression of these putative intestinal epithelial-specific transcription factors and their influence on patient outcome. PATIENTS AND METHODS: Fifty-three resected carcinomas of the ampulla of Vater, 31 pancreatic ductal adenocarcinomas, and 15 extrahepatic biliary carcinomas were analyzed for CDX1 and CDX2 expression using immunohistochemistry. RESULTS: Forty percent of carcinomas of the ampulla of Vater but less than 5% of pancreatic and biliary adenocarcinomas expressed CDX. Expression of CDX was associated with a better prognosis (P = .0009). Individually, both CDX1 (P = .02) and CDX2 (P = .02) expression were associated with a survival advantage on univariate analysis. Advanced T stage (P = .02), lymph node metastases (P = .004), and vascular space invasion (P = .0009) were associated with a poor prognosis. Multivariate analysis revealed vascular space invasion (P = .01) and CDX expression (P = .01) to be independent prognostic factors. CONCLUSION: Expression of CDX was an independent marker of outcome in patients with resected adenocarcinoma of the ampulla of Vater. Expression of CDX may distinguish good prognosis intestinal-like tumors, which potentially arise within intestinal epithelium, from poorer prognosis pancreatobiliary tumors, which arise in adjacent pancreatic and/or biliary ductal epithelium.
Authors: Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay Journal: Mod Pathol Date: 2016-09-02 Impact factor: 7.842
Authors: Ioannis A Voutsadakis; Stergios Doumas; Konstantinos Tsapakidis; Maria Papagianni; Christos N Papandreou Journal: World J Gastroenterol Date: 2009-06-07 Impact factor: 5.742
Authors: Z-Q Jiang; G Varadhachary; X Wang; S Kopetz; J E Lee; H Wang; R Shroff; M Katz; R A Wolff; J Fleming; M J Overman Journal: Ann Oncol Date: 2013-05-22 Impact factor: 32.976
Authors: Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Ellen Freed; Natsumi Irahara; Juliet Philips; Jeffrey A Meyerhardt; Jason L Hornick; Ramesh A Shivdasani; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2009-07-07 Impact factor: 12.531
Authors: Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug Journal: Histopathology Date: 2009-02 Impact factor: 5.087